Clinical trials: Neoplasms, Oral
Breast Cancer
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
The purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles.
- Trial name
- SABRE (NCT00082277)
- Testing
- Anastrozole, Risedronate Sodium
- Where
- 35 sites in United States, Canada and 6 more
- Volunteers
- 237 people
- Sponsor
- AstraZeneca
Cancer
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR.
- Trial name
- NCT00485719
- Testing
- XL765 (SAR245409)
- Where
- 4 sites in United States, Spain
- Volunteers
- 83 people
- Sponsor
- Sanofi
Glioblastoma, Giant Cell Glioblastoma
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
The purpose of this study is to determine the highest safe dose of XL184 administered orally in combination with temozolomide (TMZ, Temodar®) and radiation therapy (RT).
- Conditions
- Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- NCT00960492
- Testing
- XL184, temozolomide, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Exelixis
Advanced Solid Malignancies
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
This study is being carried out to see how single and multiple doses of cediranib are handled by the body (that is how they are absorbed, broken down and got rid of from the body) by measuring levels of drug in the blood in…
- Trial name
- NCT00981721
- Testing
- cediranib (RECENTIN TM, AZD2171)
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Fibroid
Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential
The primary purpose of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential.
- Trial name
- NCT00427544
- Testing
- PRA-027
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neoplasms, Breast
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
This study investigates the safety and efficacy of oral lapatinib in combination with an approved medication, paclitaxel, for patients with ErbB2 metastatic breast cancer.
- Trial name
- NCT00356811
- Testing
- Lapatinib oral tablets, Paclitaxel infusion
- Where
- 13 sites in Latvia, Poland and 2 more
- Volunteers
- 57 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic pancreatic cancer who have failed at least one prior chemotherapy regimen in either the neoadjuvant, adjuvant, or first-line metastatic…
- Trial name
- NCT00568646
- Testing
- MKC-1
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- CASI pharmaceuticals, Inc.
Non-Small-Cell Lung Cancer
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
This was a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of the ALK inhibitor LDK378 when used as single agent in patients with ALK-rearranged stage IIIB or IV NSCLC previously treated…
- Trial name
- NCT02450903
- Testing
- LDK378
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Leukemia, Myeloid
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
- Trial name
- NCT06501196
- Testing
- BH-30236, Venetoclax
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- BlossomHill Therapeutics
Cancer
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.
- Trial name
- NCT00869895
- Testing
- E7050
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
Chronic Lymphocytic Leukemia, Lymphomas
Assess the Oral Bioavailability of New ABT-263 Formulations
This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies.
- Conditions
- Chronic Lymphocytic Leukemia, Lymphomas, Leukemias
- Trial name
- NCT00743028
- Testing
- ABT-263
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Abbott
Medulloblastoma, Rhabdomyosarcoma
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other…
- Conditions
- Medulloblastoma, Rhabdomyosarcoma, Neuroblastoma, Hepatoblastoma
- Trial name
- NCT01125800
- Testing
- LDE225
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Prostate
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at…
- Trial name
- REDUCE (NCT00056407)
- Testing
- Dutasteride
- Where
- 932 sites in United States, Argentina and 40 more
- Volunteers
- 8,231 people
- Sponsor
- GlaxoSmithKline
Cancer, Solid Tumors
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans.
- Conditions
- Cancer, Solid Tumors, Lymphoma, Malignancy
- Trial name
- NCT01078649
- Testing
- Debio 1143 (AT-406)
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Debiopharm International SA
Non-small-Cell Lung Cancer
Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid
The purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.
- Trial name
- NCT03413358
- Testing
- Sheng Bai oral liquid, Platinum-based two medicine (carboplatin / cisplatin) .
- Where
- China
- Volunteers
- 240 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Peritoneal Cancer, Ovarian Cancer
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Trial name
- NCT00281632
- Testing
- GW786034
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Acute Myeloid Leukemia
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
This is a phase 1, multi-center, single-arm study to evaluate the pharmacokinetics(PK)/ pharmacodynamics(PD), safety, and clinical efficacy of orally administered Ivosidenib in Chinese subjects with R/R AML with an IDH1 mutation.
- Trial name
- NCT04176393
- Testing
- ivosidenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CStone Pharmaceuticals
Advanced Solid Malignancies
Open Label, Dose Escalation Phase I Study of AZD2281
The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies
- Trial name
- NCT00572364
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor)
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukaemia
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
A Randomized, Single Oral Dose, Open Label, Two Treatment, Crossover study to investigate the bioequivalence of the Test Product Azacitidine 300 mg Film coated tablets relative to Reference Product Onureg® 300 mg Film Coated…
- Trial name
- NCT06326697
- Testing
- Azacitidine, Onureg
- Where
- Saudi Arabia
- Volunteers
- 32 people
- Sponsor
- Hikma Pharmaceuticals LLC
Solid Tumor, Adult
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
- Trial name
- NCT05866692
- Testing
- TY-2699a
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- TYK Medicines, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.